Question 1

What Is the Body Pharm Tesamorelin 32 Pen?

Accepted Answer

The Body Pharm Tesamorelin 32 pen is a prefilled subcutaneous injection device loaded with 32 mg of tesamorelin acetate, a synthetic analogue of human growth-hormone-releasing factor (GRF). At the FDA-approved EGRIFTA clinical dose of 2 mg/day, that 32 mg load yields up to 16 doses per pen — a figure derived from the 2024 label, not a vendor-published dose count.

Tesamorelin is a 44-amino-acid GRF analogue that stimulates endogenous growth hormone release from the pituitary. It binds GHRH (growth-hormone-releasing hormone) receptors on the anterior pituitary gland, triggering pulsatile GH secretion. The FDA-approved indication is reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The molecule has been studied in LiverTox-referenced work on insulin resistance, obesity and nonalcoholic fatty liver disease, but no new FDA indication has been added through 2024.

Question 2

Who Is the Tesamorelin 32 Pen Best Suited For?

Accepted Answer

The Body Pharm Tesamorelin 32 pen is best suited to adults with clinically significant visceral adiposity who are already working with a registered prescriber on a structured body composition or metabolic protocol — specifically where visceral fat has not responded adequately to sustained dietary and training interventions. The GHRH mechanism preferentially mobilises central fat, not fat across the board. Tesamorelin is FDA-approved only for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy; any non-HIV use sits outside that label and should be a clinician-led decision.

The 2024 EGRIFTA prescribing information lists explicit contraindications: disruption of the hypothalamic-pituitary axis (including hypothalamic or pituitary tumour, pituitary surgery, head irradiation, or head trauma), because tesamorelin depends on a functional pituitary to work. Active malignancy is a contraindication because GH can promote tumour growth. Pregnancy and known hypersensitivity to tesamorelin or mannitol are also contraindicated. Breastfeeding individuals and anyone with uncontrolled diabetes or proliferative retinopathy should defer to clinician judgement before initiating, because tesamorelin raises IGF-1 and can worsen glucose control and retinal disease.

Candidates whose primary goal is appetite suppression or weight loss through caloric reduction are usually a poor mechanistic fit. Tesamorelin is a GHRH analogue, not a satiety agent, and does not reduce hunger. Those buyers should compare the GLP-1/GIP pathway of the Body Pharm Tirzepatide 30 Pen, or look at mitochondrial-targeted options like the Body Pharm MOTS-C 32 Pen, and discuss with a doctor which mechanism aligns with the outcome they actually want.

Question 3

How many doses are in the BodyPharm Tesamorelin 32 pen?

Accepted Answer

The pen contains 32 mg of tesamorelin total, which yields 16 daily doses at the standard 2 mg clinical dose because 32 mg ÷ 2 mg per dose = 16 doses. If you split to 1 mg daily for a maintenance or tolerance protocol on prescriber advice, the same pen covers 32 days. Always confirm the labelled concentration and fill volume on the carton against the batch insert before first use.

Question 4

What is the standard clinical dose of tesamorelin?

Accepted Answer

The FDA-approved EGRIFTA dose is 2 mg subcutaneously once daily, injected into the abdomen. That dose was established in the HIV-associated lipodystrophy trials and remains the only dosing schedule on the 2024 label.

Question 5

Is tesamorelin FDA-approved?

Accepted Answer

Yes. Tesamorelin is FDA-approved for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, and the EGRIFTA label was updated in 2024 with no new indication added. It is not FDA-approved for general body composition, obesity, or NAFLD, though LiverTox notes ongoing evaluation in those areas.

Question 6

How should the pen be stored?

Accepted Answer

Store the pen refrigerated at 2–8 °C, protected from light, and do not freeze. Freezing denatures the peptide. Once in use, follow the manufacturer’s in-use stability window on the carton insert and discard if the solution is cloudy or discoloured.

Question 7

Can tesamorelin be used for body composition without HIV?

Accepted Answer

There is no FDA-approved non-HIV indication as of the 2024 label. LiverTox records that tesamorelin is being studied for insulin resistance, obesity, and NAFLD, but published efficacy outside the HIV population is not established in the sources reviewed here. Off-label use is a clinical decision that belongs with a registered prescriber, and the Body Pharm MOTS-C 32 Pen or Body Pharm Tirzepatide 30 Pen may be more mechanistically appropriate depending on the goal.

Attribute	Detail
Availability	InStock
SKU	bptes32
Shipping	South Africa only; cold-chain with gel pack

Item	Quantity	Notes
Tesamorelin pen	1	Pre-filled, 32 mg stated content, lyophilised
Needles	8	For subcutaneous injection
Certificate of Analysis	Available on request	Batch-specific; email or product page download

Documented on our listing	Confirm before purchase	Not established by the listing
Listed price; InStock status	Batch number on your specific pen matches the CoA you receive	Independent laboratory accreditation
Lyophilised 32 mg stated content; 3 mL fill volume	Test date falls within acceptable stability window	Formal purity acceptance threshold
Third-party tested for purity and identity (claimed)	Identity method (e.g., mass spectrometry) is specified	Pen calibration: delivered mg per click
CoA available on page or by email	Cold-chain integrity on arrival (gel pack present, temperature appropriate)	Reconstitution instructions for this specific pen
One pen, eight needles included		Post-opening stability duration
		Clinical equivalence to FDA-labelled EGRIFTA SV

FDA-labelled use	Off-label/investigational context
HIV-associated lipodystrophy with excess abdominal fat	General visceral fat reduction in HIV-negative adults
1.4 mg daily dose (EGRIFTA SV 2 mg vial reconstituted)	Body composition or athletic performance claims
Established cardiovascular and metabolic safety data in labelled population	Long-term safety not established outside indicated use

Path	Best for	Action
Buy this pen	You need tesamorelin at 32 mg with CoA-verified batch documentation	Add to cart — SKU bptes32
Verify first	You want to check the CoA, batch number and test date before committing	Email us for the current batch Certificate of Analysis
Explore alternatives	You need a different compound, strength or format	Browse the full peptide range below

Body Pharm Tesamorelin 32 Pen

What comes with the 32 mg pen

Trust checks for this pen

Listing details versus what requires verification

Approved use versus off-label body composition

Order this pen or compare the full range

Ways to proceed

What to confirm before ordering

Sources

Reviews